Dr. Anil Singhvi, MD · 35+ years · Founded Madhya Pradesh's first hematology centreConsult in person in Indore, or by video call.
Book on WhatsApp
or call +91 98263 73337
A common blood cancer of plasma cells — once difficult to treat, now highly controllable with modern drugs, letting patients live active lives for years.
Dr. Anil Singhvi, MD · 35+ years · Founded Madhya Pradesh's first hematology centreConsult in person in Indore, or by video call.
Multiple myeloma is a cancer of plasma cells, the antibody-producing cells of the bone marrow. The abnormal cells crowd the marrow and produce an abnormal protein, leading to anemia, bone damage, high calcium, and kidney problems.
Myeloma treatment has improved more than almost any other cancer. New drug combinations control the disease effectively, protect the bones and kidneys, and are increasingly affordable in India. Most patients respond well and return to their routine activities.
Diagnosis is made with blood and urine tests for the abnormal (M) protein, a bone marrow examination, and imaging of the bones. These tests also stage the disease and identify risk features that guide how intensive treatment should be.
Treatment uses combinations of novel agents — proteasome inhibitors (like bortezomib), immunomodulatory drugs (like lenalidomide), and steroids — most of them given on a day-care basis or as tablets at home. Suitable younger patients may be offered stem cell transplantation to deepen the response. Bone-protecting medicines and supportive care are part of every plan.
This information is for general education and is not a substitute for a consultation. Every patient is unique — the right treatment can only be decided after proper evaluation.
How multiple myeloma treatment has become easier and more effective.
Beating multiple myeloma — what every patient should know.
Get an expert opinion from a specialist with over three decades of experience treating cancers and blood disorders. Second opinions and online consultations welcome.
Book on WhatsApp